Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Curious...did you happen to just 'stumble' on this information?
Amen!
Fortunately, your posts are infrequent enough to tolerate...but your descriptive language is not. Please, in the future, refrain from such immature ranting and 'clean' up your act. Keep your posts about the company and/or the stock but do so in a decent manner. Otherwise, most on this board would be grateful if you took your 10000 shares elsewhere...this is most likely not just my opinion only (NJMOO).
BHRT SEC filed "information sheets"
I do appreciate your right to an opinion as to what constitutes quality research...However, I believe a variety of information at my disposal helps me to be a more informed investor. Thank you for your efforts...I must commend you on your persistence.
Thank you...very well done.
Thank you, pijoe...I appreciate your thoughtful comment and your optimism.
Your post is very illuminating...to all I'm certain. Thank you for not disappointing.
Thank you for your inquiry. I'd be more than happy to clarify my comments, but I first would like an answer from you...is there anything positive you can say regarding Bioheart (research time in the regenerative field, ambition to eradicate some of the most horrific diseases inflicting the world today, qualifications of the Chief Scientific Officer, etc.). This company can't be ALL bad, can it? I look forward to your reply.
"THAT is what a quarterly 10-Q and 10-K are for. "
This is just ONE of many tools that can be used to a evaluate a company and its stock...I know it is the only one you rely on for analysis. That is not true for all investors...I find it VERY short-sighted to do so, IMO.
This was VERY informative...regarding trial status, financials, company goals, etc. I strongly recommend to everyone that has a sincere interest in a factual, unbiased assessment as to Bioheart's future, listen to this audio broadcast...it was well worth the approximate 20 minutes to do so.
In my opinion, anyone without a biased agenda would also agree.
What about the desire for a company, ANY company, to target valuable resources towards treatment of a horrific disease such as MS? Is this effort at least not worth some positive commentary on your part?
So what exactly are you implying...and please, be succinct as possible.
I believe this to be true. I am in medical sales and there is always a significant advantage to being first-in-class or first-to-market...if the therapy proves itself then financial stability will follow. The race is to see who is first...if Bioheart is able to be successful in this endeavor, then much of what has been challenged on this board will be a settled debate. This is why the persistent effort to frame the debate by those whose financial holdings stand to benefit from Bioheart being second, or worse. I'm of the opinion Bioheart is not just in the enviable position to be first, but will be.
That was rude and unnecessary (IMO)
"Whatever. You're entitled to your opinion. and I'm entitled to mine."
On this we can agree. There can, however, be a line between opinion and accusation. Just because you have not had success in trading in penny stocks doesn't mean others have not.
"Anyone that would tell you - or claim - that the majority of the penny stocks they pick are winners, well, they are liars "...
You forgot to claim this is just your opinion...how can you be certain all are lying? I find that statement a bit to conclusive for my tastes (IMO).
Since we're all speaking in the arena of opinion...mine has never changed. If Bioheart can manage to avoid bankruptcy, which I strongly believe they will, the company will eventually succeed. Success may be through a joint venture, or what I anticipate and am hoping for...successful results of the pivotal Phase 3 trials (either Mirror and/or Marvel 2). Then MyoCell, when approved by the FDA, will be the very first stem cell treatment for heart failure...a disease that is largely responsible for the majority of hospitalizations in the US, and a significant number of deaths worldwide. Yes...it is indeed possible for this stock to climb to the dollar range. Is it probable? If what I stated occurs...Absolutely! Bioheart has the real potential to be THE success story in regards to a reversal of fortunes. And that is precisely what will happen to those few who have believed and continue to believe...they will make a fortune.
"Makes zero sense IMHO. None."
You're post makes zero sense to me...None. IMHO
And there is no feasible way possible to spin this any other way than for what it obviously is... GOOD news.
I don't believe you are alone in your thinking...there is at least one other who shares your views. But you are certainly in the minority...almost all of those that take precious time to visit this forum do so because we are encouraged by the potential.
Great post Investaholic...you may even want to BOLD the word 'increased' for added effect...IMO.
The positive financial assessment for the first Quarter 2014 was encouraging...Net income (loss) $677,440, at least a positive figure, and I'm not intending to 'spin' this into more than it is. I was hoping to see a reference to the Mirror Trial...any thoughts as to why it may have been excluded? Thank you.
Bioheart MyoCell Endorsed by Opinion Leaders and Leading Centers
Heart failure is leading cause of hospitalization in the USA and the leading economic drain on Medicare.
Bioheart MyoCell with only one half hour injection session is out performing all other therapies. The 2nd generation Bioheart MyoCell SDF-1 has pre-clinical data from Cleveland Clinic and the University of Florida supporting an expected doubling of improvement over the original MyoCell composition (54% compared to 27%). A Bioheart sponsored study published in the European Heart Journal documents an expected even greater improvement from repeat injection sessions. 33 leading heart failure centers in the USA participated in the Bioheart Phase II/III MARVEL study Part I. Every single one of the Institutional Review Boards that reviewed the safety and efficacy data dating back to 1988 in large animals and 2000 in humans approved the study.
MARVEL Bioheart MyoCell Results in Exercise Capacity Improvement Compared to Other Therapies
Bioheart MyoCell 95.7 over Placebo Pts on Optimal CHF Drugs - 4 meters decline ($8 billion is spent on CHF drugs each year with minus 4 meters decline results - drug companies say this is a bargain since no treatment pts have minus 20 meters decline) Bioheart MyoCell 95.7 vs Mesoblast MPCs 53 meters (Mesoblast is valued at over $2 billion)
Bioheart MyoCell 95.7 vs. Osiris Bone Marrow Cells Allogeneic 10 meters
Bioheart MyoCell 95.7 vs Capricor Cardiac Cells 52 meters
Bioheart MyoCell 95.7 vs Cardio-3 Cardiac Cells 52 meters
Bioheart MyoCell 95.7 vs Cytori fat derived cells 52 meters (Cytori has spent nearly $300 million developing their cell therapies almost double what Bioheart has invested)
Bioheart MyoCell 95.7 vs No Treatment -20 meters decline
Bioheart MyoCell 95.7 vs CRT Pacers 16 to 20 meters (Over $3 billion is spent each year on CRT pacers)
This is all with one half hour injection session with a 1999 developed 1st gen. Bioheart MyoCell composition. 2nd gen. Bioheart MyoCell SDF-1 and repeated injections are expected to more than double improvement. Bioheart has achieved superior results to all other therapies for heart failure to date. Solid team. Solid technology. Solid results. The MIRROR study is on track for success and FDA approval.
"Bioheart's closest to market competitor is Cardio3. They started enrollment after a successful public offering last June. Even though they started enrollment around the same time as Bioheart, they need 270 patients while Bioheart needs 130 to complete phase 3 enrollment. I would imagine there is a list of patients waiting to enroll for Mirror and or Marvel. Cardio3 mentioned on one of their press releases or their website that they are on track to complete enrollment by the end of this year. It's a race to the finish now!
I recall reading that Myocell performed superior to Cardio3 cardiac stem cells and bone marrow cells in the phase 2 trials."
You recalled correctly...Myocell was superior to ALL competitors (it was not head-to-head studies, but regarding meters walked during 6min test, Bioheart's Myocell was almost double to others).
Thank you for your post, andyshow. There was nothing in what you stated that was deserving of either criticism or condescension...Your opinion is a valid and welcomed one.
You may be right...what you stated regarding the future status of this company and the field may prove to be 100% correct...but then, maybe it isn't. But if it isn't Bioheart that succeeds, and if their failure is do to their own mistakes, mismanagement, etc...then they should fail...All I want is for them to have that opportunity, apart from any efforts from others to enhance the demise. If their role in the paradigm shift in medicine from treating symptoms to curing disease is to pave the way for another company to do it better, the world will still be better off, and I'd still be grateful for their efforts and vision. Bioheart does not have to succeed for my hope to come to pass...their failure does if others are to succeed.
In the end, and possibly very soon, we shall see if either of us had it right.
Parm...you will, as I suspect, do your due diligence...I have no reason to believe otherwise. Others may recommend various documents for you to discern. I would only suggest the article I mentioned in my previous reply to your question be among the literature you review. I believe I answered your question factually and without motive,' objective' I believe was your thoughtful description.
Thank you, Parm...and know that I hold you in high regard as well. Concerning the trials, the MyoCell trial with the most near-term opportunity for success is the Mirror Trial...it is further along in the 'approval' process than any of the others. As its name suggests, it mirrors the Marvel Trial which was suspended, not for safety reasons, but for lack of funding (the Phase 2/3 results were published in the Oct. 2011 issue of American Hwart Journal). You are correct there was mortality in the study, but causality was not shown do to MyoCell. However, there was causality with regards to ventricular arrhythmias, which appeared to be attenuated with prophylactic amiodarone (Cordarone) given during the muscle biopsy. All-in-all, safety was not a concern, nor was efficacy (same study referenced 6MWT results that were superior to any approved treatment, drug or device, for heart failure). The only difference is the catheter...Marvel utilizes the MyoStar (JNJ) while Mirror uses MyoCath (Bioheart). In addition, another reason Mirror was initiated, and as a Phase 3 double-blinded, placebo-controlled study, was to not interfere with Marvel designation for expanded access. This was the FDA's suggestion as to not delay the potential approval of MyoCell.
The ANGEL Trial is a Phase 1 trial studying the benefits of adipose-derived stem cells for treatment of heart disease, specifically chronic ischemic cardiomyopathy. There appears to be angiogenic properties with this formulation which gives it the advantage earlier in the treatment cycle post-MI. MyoCell is for rejuvenating the dead heart muscle and is the only stem cell type, to date, proven to work in necrotic scar tissue ( skeletal myoblasts).
With all do respect, I consider myself a serious investor, and I am taking this company seriously...very seriously. I congratulate you on your financial windfall, Parm...I know you were wrestling for an extended period of time as to what you should do, and were getting advice to sell from your relatives...I'm glad you were able to make a profit and are comfortable with your decision. I offer no malice towards anyone that has believed at some point in time, or still believes this company is 'dying on the vine'...most, if not all, financial signs point to this conclusion. It is not negative nor for lack of vision to hold this view...but I still hold the same position I did in 2004 when I discovered this stock, and in 2008 when I first invested, and last year when I accumulated a significant quantity of shares...nothing has changed for me, absolutely nothing. I will hold onto all of my Bioheart shares until they are worth something to me, or are worthless to all of us.
Call me a fool , but I passionately believe in this company and what they are trying to accomplish...and I am willing to lose my entire investment, if necessary, for my conviction. If I am wrong, I will be the first one to admit my failure to all on this board, and I will do so respectfully. If am right, I will be the last one to say so, as this is not about being right, but all about being on the right side of history...and that is what is at stake here...history. If Bioheart proves successful, this company and what it would have achieved in the face of insurmountable obstacles will have made history...and in doing so, improved the lives of countless millions worldwide. This was never about the money to me...it has always, and will continue to be about the cause...to help people that otherwise would be left to a life of immobility, useless and expensive treatments, or a chance at a new life with a transplant, if one is available . I hope Bioheart makes it...I am praying that it makes it...the world would be a better place if it makes it.
Amen to that, brother.
This too is a factual update, is it not?
Gsdubb, loving the long and detailed post...well done!
All I know is there seems to be way too much optimism on this board as of late...webinars, special presentations, Angel Trial update, etc. Don't you know we are in the 'last days'...please, let us return to the doom and gloom of our financing challenges. Thank you.
I believe 'webinar' should be our word for the day...what say you?
"I could be wrong"...yes, you are. (NJMO= not just my opinion)
I just finished watching the most recent webinar delivered by Kristin Comella...this is just my opinion, but it should be required viewing prior to posting on this board. I cannot imagine that anyone with an open mind and without an agenda could come to any other conclusion than this company is amazing! Yes, the financial picture is dark, dismal, horrific...pick your adjective. But the science...WOW! And that is what moves me...not all the pessimism as to why Bioheart won't succeed, but why it MUST succeed!
And, if I'm reading program agenda correctly, look which of the two conferences she is participating in...Stem cell commercialization & partnering.
And another great post...very informative and encouraging to know that the ground we cover with this stock has been walked before.
Thank you...hoping things hold together until Mirror enrollment update.